Search | OpenScholar

Search results

1498 results found

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.

Publication: Journal Article

Biglan, KM, D Oakes, AE Lang, RA Hauser, K Hodgeman, B Greco, J Lowell, et al. 2017. “A Novel Design of a Phase III Trial of Isradipine in Early Parkinson Disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.”. Ann Clin Transl Neurol.

Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B). Mov Disord 2015;30:646-54.

Publication: Journal Article

Hauser, RA, S Isaacson, JP Lisk, LA Arthur Hewitt, and G Rowse. 2015. “Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson’s Disease (nOH306B). Mov Disord 2015;30:646-54.”. Mov Disord.

Who is helping whom? Manuscript support and transfer of value. Ann Neurol 2015;77:353-5.

Publication: Journal Article

Wechsler, R, RA Hauser, and J French. 2015. “Who Is Helping Whom? Manuscript Support and Transfer of Value. Ann Neurol 2015;77:353-5.”. Ann Neurol.

Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.

Publication: Journal Article

Simon, DK, C Wu, BC Tilley, AM Wills, MJ Aminoff, J Bainbridge, RA Hauser, et al. 2015. “Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.”. Clin Neuropharmacol.

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci 2018;128:619-626.

Publication: Journal Article

Lew, MF, A Breashear, K Dashtipour, S Isaacson, RA Hauser, P Maisonobe, D Snyder, and W Ondo. 2018. “A 500 U/2 mL Dilution of AbobotulinumtoxinA Vs. Placebo: Randomized Study in Cervical Dystonia. Int J Neurosci 2018;128:619-626.”. Int J Neurosci.

Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci 2018;389:1-3.

Publication: Journal Article

“Hauser RA, Truong D. Tardive Dyskinesia: Out of the Shadows. J Neurol Sci 2018;389:1-3.”. 2018. J Neurol Sci.

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 2016;31:1366-72.

Publication: Journal Article

Hauser, RA, CW Olanow, B Dzyngel, T Bilbault, H Shill, S Isaacson, J Dubow, and A Agro. 2016. “Sublingual Apomorphine (APL-130277) for the Acute Conversion of OFF to ON in Parkinson’s Disease. Mov Disord 2016;31:1366-72.”. Mov Disord.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 2017;89:2495-2502.

Publication: Journal Article

Schobel, SA, G Palermo, P Auinger, JD Long, S Ma, OS Khwaja, D Trundell, 2CARE Huntington Study Group Investigators, and . 2017. “Motor, Cognitive, and Functional Declines Contribute to a Single Progressive Factor in Early HD. Neurology 2017;89:2495-2502.”. Neurology.

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol 2014;21:736-43.

Publication: Journal Article

Hauser, RA, AH Shapira, P Barone, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2014. “Long-Term Safety and Sustained Efficacy of Extended-Release Pramipexole in Early and Advanced Parkinson’s Disease. Eur J Neurol 2014;21:736-43.”. Eur J Neurol.

Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging. J Nucl Med 2014;55:1288-1296.

Publication: Journal Article

Seibyl, JP, A Kupsch, J Booij, DG Grosset, DC Costa, RA Hauser, J Darcourt, N Bajaj, Z Walker, and . 2014. “Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects With Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging. J Nucl Med 2014;55:1288-1296.”. J Nucl Med.